» Articles » PMID: 37434804

Understanding and Treatment Strategies of Hypertension and Hyperkalemia in Chronic Kidney Disease

Overview
Date 2023 Jul 12
PMID 37434804
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension and potassium imbalance are commonly observed in chronic kidney disease (CKD) patients. The development of hypertension would be related to several mechanisms. Hypertension is related to body mass index, dietary salt intake, and volume overload and is treated with antihypertensives. In CKD patients, managing hypertension can provide important effects that can slow the progression of CKD or reduce complications associated with reduced glomerular filtration rate. The prevalence of hyperkalemia and hypokalemia in CKD patients was similar at 15-20% and 15-18%, respectively, but more attention needs to be paid to treating and preventing hyperkalemia, which is related to a higher mortality rate, than hypokalemia. Hyperkalemia is prevalent in CKD due to impaired potassium excretion. Serum potassium level is affected by renin-angiotensin-aldosterone system inhibitors and diuretics and dietary potassium intake and can be managed by potassium restriction dietary, optimized renin-angiotensin-aldosterone system inhibitor, sodium polystyrene sulfonate, patiromer, and hemodialysis. This review discussed strategies to mitigate and care for the risk of hypertension and hyperkalemia in CKD patients.

Citing Articles

A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond.

Han S, Kim S Electrolyte Blood Press. 2025; 22(2):21-28.

PMID: 39780853 PMC: 11704317. DOI: 10.5049/EBP.2024.22.2.21.


Risk and predictors of severe hyperkalemia after total parathyroidectomy without auto-transplantation in patients with secondary hyperparathyroidism.

He C, Li L, Pan J, Cheng G, Wang C, Tang Y Front Endocrinol (Lausanne). 2024; 15:1463735.

PMID: 39493772 PMC: 11527608. DOI: 10.3389/fendo.2024.1463735.

References
1.
Roger S, Lavin P, Lerma E, McCullough P, Butler J, Spinowitz B . Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant. 2020; 36(1):137-150. PMC: 7771984. DOI: 10.1093/ndt/gfz285. View

2.
Modi G, Agarwal R . What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease?. Curr Cardiol Rep. 2015; 17(11):101. DOI: 10.1007/s11886-015-0650-4. View

3.
Hall J, da Silva A, do Carmo J, Dubinion J, Hamza S, Munusamy S . Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010; 285(23):17271-6. PMC: 2878489. DOI: 10.1074/jbc.R110.113175. View

4.
Bakris G, Siomos M, Richardson D, Janssen I, Bolton W, Hebert L . ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000; 58(5):2084-92. DOI: 10.1111/j.1523-1755.2000.00381.x. View

5.
McMurray J, Krum H, Abraham W, Dickstein K, Kober L, Desai A . Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016; 374(16):1521-32. DOI: 10.1056/NEJMoa1514859. View